Physician profile
Arunkumar Modi
NPI 1619137247
$6,049.03
in general payments reported to CMS, 2019-2025
14 companies · $5,682 in 2025
The $5,682 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $150 · 2023: $200 · 2024: $16.88 · 2025: $5,682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,388 · Food and Beverage: $1,205 · Travel and Lodging: $1,013 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $200 · Education: $92.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,387.50 |
| Food and Beverage | $1,205.08 |
| Travel and Lodging | $1,013.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $200.00 |
| Education | $92.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genetix Biotherapeutics INC | $4,869.41 | 2025 | Lyfgenia |
| Genzyme Corporation | $200.00 | 2023 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Janssen Biotech, INC. | $150.00 | 2025 | Rybrevant, Carvykti |
| Janssen Research & Development, LLC | $146.14 | 2025 | |
| Daiichi Sankyo INC. | $128.34 | 2025 | Vanflyta |
| Celgene Corporation | $127.61 | 2025 | Breyanzi |
| Sanofi-Aventis U.S. LLC | $92.99 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $59.84 | 2025 | Iclusig |
| Kite Pharma, INC. | $52.94 | 2025 | Yescarta |
| Legend Biotech USA INC. | $28.38 | 2025 | Carvykti |
| Genentech USA, INC. | $26.50 | 2025 | Columvi |
| Novartis Pharmaceuticals Corporation | $16.88 | 2024 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arunkumar Modi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.